222 related articles for article (PubMed ID: 6124197)
1. Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications.
Colucci WS
Ann Intern Med; 1982 Jul; 97(1):67-77. PubMed ID: 6124197
[TBL] [Abstract][Full Text] [Related]
2. Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.
Stanaszek WF; Kellerman D; Brogden RN; Romankiewicz JA
Drugs; 1983 Apr; 25(4):339-84. PubMed ID: 6303744
[TBL] [Abstract][Full Text] [Related]
3. The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril).
Kluger J; Cody RJ; Laragh JH
Am J Cardiol; 1982 May; 49(7):1667-74. PubMed ID: 7044087
[TBL] [Abstract][Full Text] [Related]
4. Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
Packer M; Medina N; Yushak M
J Am Coll Cardiol; 1986 Mar; 7(3):671-80. PubMed ID: 2869077
[TBL] [Abstract][Full Text] [Related]
5. Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
Frishman WH; Eisen G; Lapsker J
Med Clin North Am; 1988 Mar; 72(2):441-8. PubMed ID: 2894488
[TBL] [Abstract][Full Text] [Related]
6. Clinical, hemodynamic, and neuroendocrine effects of chronic prazosin therapy for congestive heart failure.
Colucci WS; Williams GH; Braunwald E
Am Heart J; 1981 Sep; 102(3 Pt 2):615-21. PubMed ID: 6115578
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetic, pharmacodynamic and haemodynamic effects of acute and chronic alpha-adrenoceptor blockade in chronic heart failure.
Taylor SH; Silke B
Ann Acad Med Singap; 1981 Oct; 10(4 Suppl):45-51. PubMed ID: 6124209
[TBL] [Abstract][Full Text] [Related]
8. Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure.
Colucci WS; Williams GH; Braunwald E
Ann Intern Med; 1980 Sep; 93(3):452-3. PubMed ID: 7436166
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic and neuroendocrine responses to acute and chronic alpha-adrenergic blockade with prazosin and phenoxybenzamine.
Mulvihill-Wilson J; Gaffney FA; Pettinger WA; Blomqvist CG; Anderson S; Graham RM
Circulation; 1983 Feb; 67(2):383-93. PubMed ID: 6129077
[TBL] [Abstract][Full Text] [Related]
10. Selective alpha 1-adrenergic antagonists: therapeutically relevant antihypertensive agents.
Graham RM
Am J Cardiol; 1984 Jan; 53(3):16A-20A. PubMed ID: 6141721
[TBL] [Abstract][Full Text] [Related]
11. Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure.
Stein L; Henry DP; Weinberger MH
Am J Med; 1981 Apr; 70(4):825-32. PubMed ID: 7011023
[TBL] [Abstract][Full Text] [Related]
12. Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
Izzo JL; Licht MR; Smith RJ; Larrabee PS; Radke KJ; Kallay MC
Am J Cardiol; 1987 Aug; 60(4):303-8. PubMed ID: 2887102
[TBL] [Abstract][Full Text] [Related]
13. Management of refractory congestive heart failure with prazosin.
Awan NA; Evenson MK; Needham KE; Mason DT
Am Heart J; 1981 Sep; 102(3 Pt 2):626-34. PubMed ID: 6267922
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of prazosin effect on cardiac output in chronic heart failure.
Arnold SB; Williams RL; Ports TA; Baughman RA; Benet LZ; Parmley WW; Chatterjee K
Ann Intern Med; 1979 Sep; 91(3):345-9. PubMed ID: 475164
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
Reid JL; Vincent J
Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic application of prazosin in chronic refractory congestive heart failure. Tolerance and "tachyphylaxis" in perspective.
Awan NA; Needham KE; Evenson MK; Amsterdam EE; Mason DT
Am J Med; 1981 Jul; 71(1):153-60. PubMed ID: 7246573
[TBL] [Abstract][Full Text] [Related]
17. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
Titmarsh S; Monk JP
Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
[TBL] [Abstract][Full Text] [Related]
18. Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy.
Laslett LJ; DeMaria AN; Amsterdam EA; Mason DT
Arch Intern Med; 1978 May; 138(5):819-20. PubMed ID: 646547
[TBL] [Abstract][Full Text] [Related]
19. [Vasodilator therapy with alpha-receptor blockaders. Acute and chronic effect of prazosin and phentolamine in congestive heart failure].
Kersting F; Samosny G; Kasper W; Schuster HP
Med Welt; 1981 Jun; 32(26):1040-5. PubMed ID: 6114383
[No Abstract] [Full Text] [Related]
20. Contribution of the renin-angiotensin-aldosterone system to development of tolerance and fluid retention in chronic congestive heart failure during prazosin treatment.
Riegger GA; Haeske W; Kraus C; Kromer EP; Kochsiek K
Am J Cardiol; 1987 Apr; 59(8):906-10. PubMed ID: 3548307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
